The selective presence of immunosuppressive cells in high PI4KA-expressing tumors implies that PI4KA activity contributes to tumor growth, and anti-PI4KA therapies have the potential to reverse suppressive phenotype in metastatic prostate cancers. Here, PI4KA is linked to Familial prostate cancer.